GSK’s Exdensur receives Japan’s MHLW approval for severe asthma and chronic rhinosinusitis with nasal polyps: London, UK Wednesday, January 7, 2026, 10:00 Hrs [IST] GSK plc an ...

AstraZeneca announces Saphnelo self-administration phase III TULIP-SC trial demonstrates statistically significant and clinically meaningful reduction in SLE disease activity ...

The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...

Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and ...

The Cellares Cell Shuttle platform was the first to receive the FDA’s Advanced Manufacturing Technology (AMT) designation, which offers partners additional touchpoints and priority review mechanisms ...

As the air turns considerably colder, it is natural for extremities such as hands and feet to feel chilly. However, if this ...

Medically reviewed by Jamie Johnson, RDN Key Takeaways Zinc may help prevent cold symptoms or shorten the length of a ...

Autolus Therapeutics plc , a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the first Integrated ...

GSK has secured approval in Japan for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps. Approved by Japan’s ...

Patients with SSc were linked to an increased risk for hematological malignancies, specifically B-cell malignancies.

Many people with multiple sclerosis struggle with balance and coordination, and this study uncovers a hidden reason why.

Mothers with MS face longer diagnostic delays than women without children, especially those who are employed or single.